250 related articles for article (PubMed ID: 28881714)
1. The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Radin M; Fenoglio R; Baldovino S; Menegatti E
Oncotarget; 2017 Aug; 8(32):52072-52077. PubMed ID: 28881714
[TBL] [Abstract][Full Text] [Related]
2. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Thiel J; Hässler F; Salzer U; Voll RE; Venhoff N
Arthritis Res Ther; 2013 Sep; 15(5):R133. PubMed ID: 24286362
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
6. Novel Therapies for ANCA-associated Vasculitis.
Monti S; Brandolino F; Milanesi A; Xoxi B; Delvino P; Montecucco C
Curr Rheumatol Rep; 2021 Apr; 23(6):38. PubMed ID: 33909172
[TBL] [Abstract][Full Text] [Related]
7. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
[TBL] [Abstract][Full Text] [Related]
8. B-cell-targeted therapy in systemic vasculitis.
Lally L; Spiera R
Curr Opin Rheumatol; 2016 Jan; 28(1):15-20. PubMed ID: 26599379
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.
Calich AL; Puéchal X; Pugnet G; London J; Terrier B; Charles P; Mouthon L; Guillevin L;
J Autoimmun; 2014 May; 50():135-41. PubMed ID: 24703438
[TBL] [Abstract][Full Text] [Related]
10. Remission Induction Therapy with Rituximab for Microscopic Polyangiitis: A Feasibility Study.
Saito A; Takeuchi Y; Kagaya S; Ojima Y; Fukami H; Sato H; Matsuda K; Nagasawa T
Tohoku J Exp Med; 2017 May; 242(1):53-62. PubMed ID: 28539536
[TBL] [Abstract][Full Text] [Related]
11. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
Alberici F; Jayne DR
Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571
[TBL] [Abstract][Full Text] [Related]
12. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
[TBL] [Abstract][Full Text] [Related]
13. Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab.
Casal Moura M; Berti A; Keogh KA; Volcheck GW; Specks U; Baqir M
Clin Rheumatol; 2020 May; 39(5):1581-1590. PubMed ID: 31897956
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in ANCA-Associated Vasculitis.
Hassan RI; Gaffo AL
Curr Rheumatol Rep; 2017 Feb; 19(2):6. PubMed ID: 28155022
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.
Cartin-Ceba R; Golbin JM; Keogh KA; Peikert T; Sánchez-Menéndez M; Ytterberg SR; Fervenza FC; Specks U
Arthritis Rheum; 2012 Nov; 64(11):3770-8. PubMed ID: 22730028
[TBL] [Abstract][Full Text] [Related]
16. Targeted immunotherapy strategies in ANCA-associated vasculitis.
Puéchal X
Joint Bone Spine; 2019 May; 86(3):321-326. PubMed ID: 30201478
[TBL] [Abstract][Full Text] [Related]
17. Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener's): a retrospective single-center study.
Azar L; Springer J; Langford CA; Hoffman GS
Arthritis Rheumatol; 2014 Oct; 66(10):2862-70. PubMed ID: 24943239
[TBL] [Abstract][Full Text] [Related]
18. Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's).
Recillas-Gispert C; Serna-Ojeda JC; Flores-Suárez LF
Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2279-84. PubMed ID: 26507398
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.
Charles P; Néel A; Tieulié N; Hot A; Pugnet G; Decaux O; Marie I; Khellaf M; Kahn JE; Karras A; Ziza JM; Deligny C; Tchérakian C; Guillevin L;
Rheumatology (Oxford); 2014 Mar; 53(3):532-9. PubMed ID: 24282319
[TBL] [Abstract][Full Text] [Related]
20. Lower doses of rituximab in remission induction for refractory granulomatosis with polyangiitis.
Wawrzycka-Adamczyk K; Zugaj A; Włudarczyk A; Kosałka J; Sznajd J; Bazan-Socha S; Musiał J
Przegl Lek; 2014; 71(12):663-5. PubMed ID: 25951692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]